Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 233

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 233
---
 shares. 

Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration. 

98

Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. 

We expect our operating results to be subject to quarterly fluctuations. Our operating results will be affected by numerous factors, including:

•our ability to generate revenue from the sales of our product, OJEMDA;

•timing and variations in the level of expense related to the current or future development of our programs; 

•timing and status of enrollment for our clinical trials;

•results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners; 

•our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements; 

•any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;

•additions and departures of key personnel;

•strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;

•if a product candidate we develop receives marketing authorization, the timing and terms of such approval and market acceptance and demand for such product;

•the timing and cost to establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing authorization and intend to commercialize on our own or jointly with future collaborators;

•regulatory developments affecting current or future product candidates or products, if any, or those of our competitors;

•the amount of expense or gain associated with the change in value of the success payments and contingent consideration;

•changes in general market and economic conditions, such as due to rising interest rates, inflation, significant political, trade or regulatory developments, global regional conflicts and public health epidemics;

•business development activities, such as additional program in-licensing, which could result in up-front payments or increased development expenses; and

•cybersecurity incidents. 

If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn,